[{"address1": "The Mediaworks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 647, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 60, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 2530970, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Driggs", "age": 48, "title": "Senior VP of Legal Affairs & General Counsel and Secretary", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher  Williams", "age": 44, "title": "Chief Business Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthias  Will M.D.", "age": 51, "title": "Senior VP & Chief Development Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 52, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 54, "title": "Senior VP, CFO & Principal Accounting Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 59, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Miranda  Neville", "title": "Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "age": 59, "title": "Senior VP & Chief Human Resources Officer", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.36, "open": 1.35, "dayLow": 1.26, "dayHigh": 1.3643, "regularMarketPreviousClose": 1.36, "regularMarketOpen": 1.35, "regularMarketDayLow": 1.26, "regularMarketDayHigh": 1.3643, "payoutRatio": 0.0, "beta": 2.002, "forwardPE": -1.8219178, "volume": 2892685, "regularMarketVolume": 2892685, "averageVolume": 3760809, "averageVolume10days": 2161180, "averageDailyVolume10Day": 2161180, "bid": 1.31, "ask": 1.35, "bidSize": 20, "askSize": 20, "marketCap": 353968096, "fiftyTwoWeekLow": 1.105, "fiftyTwoWeekHigh": 3.99, "allTimeHigh": 53.24, "allTimeLow": 1.105, "priceToSalesTrailing12Months": 11.824951, "fiftyDayAverage": 1.5149, "twoHundredDayAverage": 1.806275, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 208855072, "profitMargins": 0.0, "floatShares": 118518093, "sharesOutstanding": 266141411, "sharesShort": 11821704, "sharesShortPriorMonth": 10606444, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0444, "heldPercentInsiders": 0.18086, "heldPercentInstitutions": 0.80627996, "shortRatio": 2.83, "shortPercentOfFloat": 0.0585, "impliedSharesOutstanding": 266141411, "bookValue": 1.302, "priceToBook": 1.0215054, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -227780992, "trailingEps": -0.87, "forwardEps": -0.73, "enterpriseToRevenue": 6.977, "enterpriseToEbitda": -0.799, "52WeekChange": -0.6125356, "SandP52WeekChange": 0.1198014, "quoteType": "EQUITY", "currentPrice": 1.33, "targetHighPrice": 12.0, "targetLowPrice": 5.0, "targetMeanPrice": 9.2, "targetMedianPrice": 10.0, "recommendationMean": 1.1, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 454279008, "totalCashPerShare": 1.707, "ebitda": -261311008, "totalDebt": 309166016, "quickRatio": 7.819, "currentRatio": 8.426, "totalRevenue": 29934000, "debtToEquity": 89.235, "revenuePerShare": 0.115, "returnOnAssets": -0.21431999, "returnOnEquity": -0.52105, "grossProfits": -154510000, "freeCashflow": -237942880, "operatingCashflow": -263020000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -2.92582, "financialCurrency": "USD", "symbol": "AUTL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 3760809, "fiftyTwoWeekLowChange": 0.22500002, "fiftyTwoWeekLowChangePercent": 0.20361993, "fiftyTwoWeekRange": "1.105 - 3.99", "fiftyTwoWeekHighChange": -2.6599998, "fiftyTwoWeekHighChangePercent": -0.6666666, "fiftyTwoWeekChangePercent": -61.25356, "earningsTimestamp": 1762954200, "earningsTimestampStart": 1762954200, "earningsTimestampEnd": 1762954200, "earningsCallTimestampStart": 1762954200, "earningsCallTimestampEnd": 1762954200, "isEarningsDateEstimate": false, "corporateActions": [], "postMarketTime": 1762559521, "regularMarketTime": 1762549201, "exchange": "NMS", "messageBoardId": "finmb_562879769", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1529674200000, "postMarketChangePercent": 2.2481167, "postMarketPrice": 1.3599, "postMarketChange": 0.029899955, "regularMarketChange": -0.03, "regularMarketDayRange": "1.26 - 1.3643", "epsTrailingTwelveMonths": -0.87, "epsForward": -0.73, "epsCurrentYear": -0.8311, "priceEpsCurrentYear": -1.6002889, "fiftyDayAverageChange": -0.18489993, "fiftyDayAverageChangePercent": -0.12205421, "twoHundredDayAverageChange": -0.47627497, "twoHundredDayAverageChangePercent": -0.26367798, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.1 - Strong Buy", "marketState": "CLOSED", "regularMarketChangePercent": -2.20588, "regularMarketPrice": 1.33, "displayName": "Autolus Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-08"}]